VolitionRx claims >99% pure cancer ctDNA
VolitionRx announced a ctDNA sequencing breakthrough that reportedly yields >99% pure cancer DNA from blood—positioning a novel liquid‑biopsy approach for thousands of biomarkers. The claim, if validated, could shift demand toward high‑throughput molecular assays and new cytology–molecular interfaces. (x.com)
VolitionRx issued an investor‑relations press release distributed via PR Newswire from Henderson, Nevada on March 18, 2026 under the company name VolitionRx Limited (NYSE American: VNRX). (prnewswire.com) Corporate filings and the company profile list Capture‑Seq™ and Capture‑PCR among Volition’s cfDNA product lines. (finance.yahoo.com) The announcement says an updated manuscript titled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP‑seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy" has been submitted. (ir.volition.com) Volition’s release states the manuscript was submitted in November 2025 and was previously announced in December 2025, and quotes Chief Scientific Officer Dr. Jake Micallef describing near‑absence of CTCF‑bound DNA in healthy plasma versus enrichment in cancer patient plasma. (prnewswire.com) The company describes a two‑step workflow that pairs physical enrichment of protected cfDNA fragments with bioinformatic removal of non‑tumor cfDNA sequences, and explicitly notes the protocol captures a subset rather than all circulating tumor DNA. (prnewswire.com) Volition’s communications report early validation across initial cohorts with "no false positives" and identify a combined early‑detection and MRD total‑addressable market of approximately $36 billion while saying the company is in active discussions with global diagnostic partners to pursue commercialization. (financialcontent.com; prnewswire.com) The company’s public disclosures to date consist of the March 18 press release and the submitted manuscript referenced in that release; those investor materials and syndicated news wires do not list a completed peer‑review publication or an independent third‑party validation data set in the public documents. (ir.volition.com; prnewswire.com) VNRX closed at about $0.19 on March 19, 2026 and shows a 52‑week trading range of $0.17–$0.94, per Yahoo Finance market data accompanying the company profile. (finance.yahoo.com)
